6CM
ANRO icon

683 Capital Management’s Alto Neuroscience ANRO Stock Holding History

683 Capital Management’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-40,000
Closed -$899K – 245
2026
Q1 		$899K Sell
40,000
-24,782
-38% -$459K 0.05% 142
2025
Q4 		$1.15M Buy
+64,782
New +$816K 0.05% 128

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

683 Capital Management's ANRO Position: Q2 2026 in Review

683 Capital Management sold out of Alto Neuroscience (ANRO) in Q2 2026, closing a stake of 40,000 shares — an estimated $899K sold.

683 Capital Management first reported a position in ANRO in Q4 2025 and held it in 2 quarters. The position peaked at $1.15M in Q4 2025. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • 683 Capital Management reported no remaining Alto Neuroscience position as of Q2 2026 after selling out during the quarter.
  • 683 Capital Management sold 40,000 Alto Neuroscience shares in Q2 2026, an estimated $899K.
  • 683 Capital Management first reported a position in Alto Neuroscience in Q4 2025 and held it in 2 quarters.
  • 683 Capital Management's Alto Neuroscience position peaked at $1.15M in Q4 2025.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on 683 Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.